EvodiaBio ApS: Financial statements 2023
CVR: 42569283
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
EvodiaBio ApS (CVR 42569283) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -9,941,780 and a net result of DKK -14,056,555 compared with DKK -6,304,639 the year before. Equity in the 2023 report amounted to DKK 23,625,867. The solvency ratio was 83.9%. The company had 10 employees in the financial year.
- Gross Profit
- DKK -9,941,780
- Profit/Loss
- DKK -14,056,555
- Equity
- DKK 23,625,867
- Total Assets
- DKK 28,165,796
- Employees
- 10
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -9.9 mio. | -14.1 mio. | 23.6 mio. | 10 |
| 2022 | - | -2.9 mio. | -6.3 mio. | 37.7 mio. | 7 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
EvodiaBio ApS has published its annual report for 2022. Gross profit came to DKK -2,943,103, and the net result was DKK -6,304,639.
About EvodiaBio ApS
EvodiaBio ApS is a Danish company of the type Anpartsselskab based in Rødovre, founded in 2021. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Camilla Benedicte Kloss Fenneberg. The board consists of Jarne Elleholm (chair), Andreas Helmut Fibig, Anne Françoise Véronique Cabotin and Flemming Besenbacher. The company's owners include Jarne Elleholm, BII Holdings A/S and FormanBiotech Holding ApS. According to the 2025 annual report, the company had an average of 23 employees. In 2025, the company reported a gross profit of DKK -8,437,110 and a net result of DKK -26,798,122 compared with DKK -21,106,598 the year before. Equity in the 2025 report amounted to DKK 68,626,121.